PubMed Health⌕ Search

PubMed · 16526686

Intrinsic paramagnetic defects probe the superionic phase transition in mechanochemically synthesized AgI nanocrystals.

Abstract

Electron paramagnetic resonance (EPR) of two intrinsic paramagnetic centers generated by soft mechanochemistry of Ag and I to yield zinc blende gamma-AgI nanoparticles (approximately 38 nm) has been used for the first time to probe the gamma-alpha (body centered cubic) superionic phase transitions in AgI at (423 +/- 1) K. These results are agreeable with the differential scanning calorimetric studies. A transmission electron microscope picture shows the average crystallite size in the range of approximately 30-40 nm. A hole-type Ag-related paramagnetic center (Ag2+) with an average g = 2.21025 value is remarkably sensitive to the first-order phase transition exhibiting sharp drops at the phase transition temperature (T(t)) and complete reversibility. The T(t) is characterized by a sharp, abrupt rise in the inverse paramagnetic susceptibility 1/chi by 1 order (7.4 x 10(10) to 3.17 x 10(11) in kg m(-3)) which reflects changes in the bonding of the material. Furthermore, a sharp signal at g = 2.0019 (deltaH(PP) = 10 G) due to an electron-excess center (Ag0) as a result of Ag metal nanoclusters also formed during the mechanochemical reaction (MCR) yields an abrupt and drastic decrease in the intensity observed at T(t) = 423 K. From high-temperature (323 to 433 K) I-V characteristics, the evolution of nonohmic behavior is observed on the order of 10(-9)-10(-6) A with increasing temperature until below T(t) which becomes ohmic thereafter. The reason could be the creation of an electronic defect such as Ag0 metal nanoclusters formed during the near-equilibrium mechanochemical reaction, with the increased excess free energy favoring the formation of gamma-AgI nanoparticles.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Bharathi Mohan, C S Sunandana. 2006-03-16. Intrinsic paramagnetic defects probe the superionic phase transition in mechanochemically synthesized AgI nanocrystals.. https://doi.org/10.1021/jp055497j

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗